FDA warned Alpha Aesthetics after inspection found unvalidated sterilization and manufacturing, poor complaint handling, and missed injury reports for silicone implants.
What happened
FDA inspected the firm’s medical device operations in Carson City, NV, from July 19, 2021 through August 5, 2021 and found silicone facial and body contouring implants made under quality-system (CGMP) violations. FDA found sterilization, curing, and packaging-seal processes were not validated; complaint investigations were incomplete; corrective action and nonconforming-product controls were inadequate; and the five-year shelf life was not adequately validated. FDA also found the firm did not submit required medical device reports (MDRs) for complaints involving swelling, chronic inflammation, seroma, fracture, and explantation.
What FDA found
The firm had not validated sterilization, curing, or packaging-seal processes for its silicone implants.
21 CFR 820.75(a)The firm’s complaint files lacked details, investigation records, and justifications for not investigating implant failures and injuries.
21 CFR 820.198(a), (b), (e)A corrective and preventive action record did not assess whether a process error affected product or what caused it.
21 CFR 820.100(a)The firm did not document evaluation and disposition of nonconforming gluteal and pectoral implant lots.
21 CFR 820.90(a)The firm did not adequately validate its five-year shelf life for silicone implants.
21 CFR 820.30(g)The firm failed to submit timely serious-injury and malfunction reports and its MDR procedure did not cover electronic submission.
21 CFR 803.50(a)(1)-(2); 803.17(a)(3)
What FDA wants
FDA tells the firm to notify it in writing within 15 business days of steps taken to correct all violations, prevent recurrence, and include documentation and a timetable for any longer-term actions.
Who should pay attention
- clinics and surgeons implanting silicone body implants
- distributors or brands selling Alpha Aesthetics implants
- quality teams at small medical device manufacturers with complaint and MDR duties
This is a summary. Read the original letter on fda.gov.